Home Newsfeeds BMO Capital Maintains Outperform on Workiva, Raises Price Target to $88

BMO Capital Maintains Outperform on Workiva, Raises Price Target to $88

BMO Capital analyst Daniel Jester maintains Workiva (NYSE:WK) with a Outperform and raises the price target from $76 to $88.

byBenzinga Newsdesk

December 6, 2022

1 minute read

BMO Capital analyst Daniel Jester maintains Workiva (NYSE:WK) with a Outperform and raises the price target from $76 to $88.

Analyst Ratings

Forecasting The Future: 4 Analyst Projections For Bicycle Therapeutics

By Benzinga Insights

December 20, 9:01 AM

Bicycle Therapeutics (NASDAQ:BCYC) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from…

BCYC

Connect Biopharma To Announce Long-Term Data From The China Pivotal Trial Of Rademikibart In Patients With Moderate-To-Severe Atopic Dermatitis On November 21, 2023

By Benzinga Newsdesk

November 20, 5:42 PM

Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases

CNTB

Metaverse Meets Marijuana In NFL Legend Ricky Williams’ First-Of-Its-Kind Experience In Sports & Cannabis Space

By Maureen Meehan

September 19, 2:24 PM

Highsman, the cannabis lifestyle brand founded by Ricky Williams in late 2021 is getting into the metaverse with the opening of Highsman House, the first true virtual reality sports and cannabis experience powered

TLLTF

If You Invested $1000 In This Stock 10 Years Ago, You Would Have $3,700 Today

By Benzinga Insights

October 31, 1:56 PM

Verisk Analytics (NASDAQ:VRSK) has outperformed the market over the past 10 years by 3.4% on an annualized basis producing an average annual return of 13.86%. Currently, Verisk Analytics has a market capitalization of $28.97 billion.

VRSK

BMO Capital Maintains Outperform on Workiva, Raises Price Target to $88

Related Posts

Forecasting The Future: 4 Analyst Projections For Bicycle Therapeutics

Connect Biopharma To Announce Long-Term Data From The China Pivotal Trial Of Rademikibart In Patients With Moderate-To-Severe Atopic Dermatitis On November 21, 2023

Metaverse Meets Marijuana In NFL Legend Ricky Williams’ First-Of-Its-Kind Experience In Sports & Cannabis Space

If You Invested $1000 In This Stock 10 Years Ago, You Would Have $3,700 Today